Furthermore, plasma B cells express marker genes CD38, TNFRSF17(BCMA), and IGHG1/IGHG4, which inhibit cell growth in the early stage of NSCLC but play the opposite role of promoting cell growth in advanced tumors, thus exhibiting heterogeneity in lung cancer progression. Here, TNFRSF17 is linked to lung cancer.